Axsome Therapeutics is a biopharmaceutical company developing therapies for the management of central nervous system (CNS) conditions that have limited treatment options. Co.'s primary CNS portfolio includes: AXS-05, which is an oral, investigational N-methyl-D-aspartate receptor antagonist with multimodal activity under development for the treatment of CNS disorders; AXS-07, which is an oral, multi-mechanistic, investigational medicine under development for the acute treatment of migraine; AXS-12, which is an oral, investigational medicine in development for the treatment of narcolepsy; and AXS-14, which is an oral, investigational medicine in development for the treatment of fibromyalgia. The AXSM average annual return since 2015 is shown above.
The Average Annual Return on the AXSM average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether AXSM average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AXSM average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|